Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Gilead outlays $5bn to acquire ADC specialist Tubulis
  • M&A / Deals

Gilead outlays $5bn to acquire ADC specialist Tubulis

Pharmaceutical Technology

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

M&A / DealsRead full story

pharminent April 7, 2026 (Last updated: April 7, 2026)

Pharmaceutical Technology

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

M&A / DealsRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
Next: Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

Related Stories

  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
  • M&A / Deals

Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance

pharminent June 22, 2026

You May Have Missed

  • News

pharminent June 22, 2026
sample_feature_2026-06-22
  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.